Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | NMBR | P28336 | 10/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021320 | 0.91 | CTSS (0.69) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6020946 | 0.87 | CTSS (0.63) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6019616 | 0.86 | CTSS (0.62) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6021171 | 0.86 | CTSS (0.65) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6020613 | 0.85 | CTSS (0.59) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6019601 | 0.85 | CTSS (0.68) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6020708 | 0.85 | CTSK (0.54) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6020070 | 0.83 | CTSS (0.62) | CTSSCTSKCTSLTACR1MMP2 | |
| SCHEMBL6019142 | 0.82 | NMBR (0.65) | CTSSCTSKCTSLNMBRTACR1 | |
| SCHEMBL6019242 | 0.82 | CTSS (0.58) | CTSSCTSKCTSLTACR1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | CTSS 2720/4885CTSK 2529/4885CTSL 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.